DSM Biologics launches Australian biopharma manufacturing facility

PARSIPPANY, N.J.—DSM Biologics, a business unit of DSMPharmaceutical Products, a global business providing cGMP custom manufacturingservices across all facets of the pharmaceutical industry, has signedpreliminary agreements with the Australian government to design, build andoperate the first major Australia-based mammalian biopharmaceuticalmanufacturing facility, which will be located in Brisbane. DSM Biologics willuse the 70,000-plus square-foot facility to offer mammalian process developmentand cGMP clinical and commercial manufacturing services to Australia andclients from all over the world. Among the services it currently offers aresmall-molecule API and intermediates manufacturing, fill/finish of parenteraland solid dosage forms and large-molecule drug substance production.